Evidence map›Paper›PMID 29051160›Full record

Trial reportDiabetes care2018

The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.

Pratik B Sandesara, Wesley T O'Neal, Heval M Kelli, Ayman Samman-Tahhan, Muhammad Hammadah, Arshed A Quyyumi, Laurence S Sperling

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 5 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 5 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pratik B SandesaraDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA psandes@emory.edu.ORCID 0000-0002-2809-8789
Wesley T O'NealDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Heval M KelliDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Ayman Samman-TahhanDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Muhammad HammadahDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Arshed A QuyyumiDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Laurence S SperlingDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Emory University · US

Funding

Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
The Association between Acute Mental Stress and Electrocardiographic Left Atrial AbnormalitiesF32HL134290 · NHLBI · EMORY UNIVERSITY · PI O'NEAL, WESLEY T · 2016 to 2017
$122k
NHLBI NIH HHS F32 HL134290NIDDK NIH HHS P30 DK111024
6 · The paper itself

Abstract

objectiveThis study examined the prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND

methodsThis analysis included 3,385 patients (mean age 69 ± 9.6 years; 49% male; 89% white) with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT). Diabetes and microvascular complications were ascertained by self-reported history and medical record review. Microvascular complications included neuropathy, nephropathy, and retinopathy. Outcomes included hospitalization, hospitalization for heart failure, death, and cardiovascular death. Cox regression was used to examine the risk of each outcome associated with diabetes and microvascular complications.

resultsOf the 1,109 subjects (32%) with diabetes, 352 (32%) had at least one microvascular complication. Patients with diabetes and microvascular complications had an increased risk for hospitalization (no diabetes: referent; diabetes + no microvascular complication: hazard ratio [HR] 1.18, 95% CI 1.01, 1.37; diabetes + microvascular complications: HR 1.54, 95% CI 1.25, 1.89;

conclusionsDiabetes is associated with adverse cardiovascular outcomes in HFpEF, and the inherent risk of adverse outcomes in HFpEF patients with diabetes varies by the presence of microvascular complications.

Indexed as

Stroke VolumeAgedCreatinineDiabetes ComplicationsDiabetes MellitusDouble-Blind MethodEndpoint DeterminationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansInsulinMaleMiddle AgedMineralocorticoid Receptor AntagonistsCreatinineInsulinMineralocorticoid Receptor Antagonists

Identifiers

PMID29051160
PMCPMC5741155
OpenAlexW2765144120

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.